Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804695 | 0.90 | PRMT1 (0.41) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL4922650 | 0.87 | EGFR (0.47) | MAPTCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2805416 | 0.86 | PRMT1 (0.42) | MEN1KMT2AMAPTPRMT1HPGD | |
| SCHEMBL2808819 | 0.85 | CCNB2 (0.40) | MAPTPRMT1CCNB2CDK1CCNB1 | |
| SCHEMBL4926205 | 0.85 | CASP6 (0.42) | MEN1KMT2ACCNB2CDK1CCNB1 | |
| SCHEMBL4921347 | 0.85 | MEN1 (0.46) | MEN1KMT2AMAPTPKMCCNB2 | |
| SCHEMBL4923846 | 0.85 | POLB (0.48) | NPSR1MEN1KMT2AMAPTPKM | |
| SCHEMBL4916566 | 0.85 | CCNB2 (0.39) | NPSR1MEN1KMT2AMAPTPKM | |
| SCHEMBL4925510 | 0.85 | PRMT1 (0.43) | MEN1KMT2AMAPTGAAPRMT1 | |
| SCHEMBL2803759 | 0.84 | CCNB2 (0.47) | GAACCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203451-B1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2014-07-30 | — | — | EP | claimed |
| US-20130130906-A1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO) PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | FREIE UNIVERSITAT BERLIN (DE) | 2013-05-23 | — | — | US | claimed |
| US-20100240537-A1 | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | FREIE UNIVERSITAT BERLIN (DE) | 2010-09-23 | — | — | US | claimed |
| EP-2203451-A2 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2010-07-07 | — | — | EP | claimed |
| WO-2009043320-A2 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2009-04-09 | — | — | WO | claimed |
| EP-2563801-B1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5´-MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATION CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2014-09-24 | — | — | EP | disclosed |
| EP-2203451-B1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20130130906-A1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO) PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | FREIE UNIVERSITAT BERLIN (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240537-A1 | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | FREIE UNIVERSITAT BERLIN (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2203451-A2 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita palackeho V Olomouci (CZ) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009043320-A2 | SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130906-A1 | SUBSTITUTED 6-(ALKYLBENZYLAMINO) PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES | ADORA2A, ADORA1, GART | NPSR1 103/4885MEN1 2235/4885KMT2A 3395/4885 |
| US-20100240537-A1 | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | ADORA2A, P2RY6, P2RY1 | NPSR1 79/4885MEN1 2163/4885KMT2A 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.